Results 1 to 10 of about 6,097 (116)

CCR5 as a Therapeutic Target in HIV Disease: From CRISPR/Cas9 Gene Editing to Maraviroc-Mediated Inhibition [PDF]

Viruses
The C-C chemokine receptor type 5 (CCR5) is the principal co-receptor for R5-tropic HIV-1 and remains one of the most promising therapeutic targets in the pursuit of an HIV cure.
Uzair Iqbal, Khadija Khalid, Mohamed Shaltout, Yunus Yukselten, Richard E. Sutton   +4 more
doaj   +2 more sources

Maraviroc attenuates orbital remodeling, inflammation, and lipid dysregulation in a murine model of thyroid eye disease associated with Graves’ disease [PDF]

Frontiers in Endocrinology
BackgroundGraves’ disease (GD) is an autoimmune condition that can extend beyond the thyroid, leading to thyroid eye disease (TED), a disorder marked by orbital inflammation and tissue remodeling.MethodsWe explored the therapeutic potential of maraviroc,
Fahimeh Hashemi Arani, Anne Gulbins, Mareike Horstmann, Insa Nolte, Anke Daser, Nikolaos E. Bechrakis, J Paul Banga, Erich Gulbins, Anja Eckstein, Gina-Eva Görtz   +9 more
doaj   +2 more sources

Maraviroc Inhibits SARS-CoV-2 Through Variant-Dependent Effects on Viral Entry and Mpro Activity Using Single-Round Infectious Particle and Virus-like Particle Models [PDF]

Viruses
Maraviroc (MVC), a CCR5 antagonist, has been proposed as a potential antiviral agent against SARS-CoV-2; however, its mechanism of action across viral variants remains unclear. Here, we evaluated the antiviral activity of MVC against SARS-CoV-2 wild-type
Uyen Nguyen Phuong Le, Po-Ju Chen, Li-Wei Chu, Jane Cynthia Arifin, Chih-Hao Chen, Yu-Hsuan Chen, Wen-Chi Su, Po-Ren Hsueh, Yueh-Hsin Ping, Cheng-Wen Lin   +9 more
doaj   +2 more sources

Maraviroc attenuates inflammation-exacerbated cognitive and amyloid pathology in an early-stage Alzheimer’s disease mouse model [PDF]

Translational Psychiatry
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder characterized by progressive cognitive decline, and increasing evidence indicates that systemic inflammation can accelerate disease progression.
Chang Liu, Ting Zhang, Er-Deng E, Tian-Yang Xu, Fei-Ran Yang, Jia-Wen Li, Qing Shang, Zhong-Yu Zhang, Hao-Wei Shen, Xiao-Qin Zhang   +9 more
doaj   +2 more sources

Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants

HIV Research & Clinical Practice, 2022
Background Fostemsavir is an oral prodrug of temsavir, a first‐in‐class attachment inhibitor that binds HIV‐1 gp120, preventing initial HIV attachment and entry into host immune cells.
Mary Beth Wire, Mindy Magee, Peter Ackerman, Cyril Llamoso, Katy Moore   +4 more
doaj   +1 more source

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. [PDF]

PLoS ONE, 2010
Maraviroc treatment for HIV-1 infected patients results in larger CD4(+) T cell rises than are attributable to its antiviral activity alone. We investigated whether this is due to modulation of T cell activation and inflammation.Thirty maraviroc-treated ...
Nicholas Funderburg, Magdalena Kalinowska, James Eason, James Goodrich, Jayvant Heera, Howard Mayer, Natasa Rajicic, Hernan Valdez, Michael M Lederman   +8 more
doaj   +1 more source

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc. [PDF]

PLoS ONE, 2015
Maraviroc is an HIV entry inhibitor that alters the conformation of CCR5 and is poorly efficient in patients infected by viruses that use CXCR4 as an entry coreceptor.
Christophe Rodriguez, Cathia Soulié, Anne-Geneviève Marcelin, Vincent Calvez, Diane Descamps, Charlotte Charpentier, Philippe Flandre, Patricia Recordon-Pinson, Pantxika Bellecave, Jean-Michel Pawlotsky, Bernard Masquelier, ANRS AC11 Study Group   +11 more
doaj   +1 more source

CCR5 Antagonist Maraviroc Inhibits Acute Exacerbation of Lung Inflammation Triggered by Influenza Virus in Cigarette Smoke-Exposed Mice

Pharmaceuticals, 2021
Influenza A virus (IAV) infection is a common cause of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Since macrophage inflammatory protein 1 α, a chemokine that acts through CC-chemokine receptor (CCR)-5, appears elevated in COPD
Maximiliano Ruben Ferrero, Cristiana Couto Garcia, Marcella Dutra de Almeida, Jullian Torres Braz da Silva, Daniella Bianchi Reis Insuela, Tatiana Paula Teixeira Ferreira, Diego de Sá Coutinho, Carolina Trindade de Azevedo, Patrícia Machado Rodrigues e Silva, Marco Aurélio Martins   +9 more
doaj   +1 more source

Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial. [PDF]

PLoS ONE, 2015
The immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore,
Steven F L van Lelyveld, Julia Drylewicz, Maaike Krikke, Ellen M Veel, Sigrid A Otto, Clemens Richter, Robin Soetekouw, Jan M Prins, Kees Brinkman, Jan Willem Mulder, Frank Kroon, Ananja Middel, Jori Symons, Jori Symons, Annemarie M J Wensing, Monique Nijhuis, José A M Borghans, Kiki Tesselaar, Andy I M Hoepelman, MIRS study group   +19 more
doaj   +1 more source

Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC)

Frontiers in Medicine, 2023
Post-acute sequelae of COVID (PASC), or long COVID, is a multisystem complication of SARS-CoV-2 infection that continues to debilitate millions worldwide thus highlighting the public health importance of identifying effective therapeutics to alleviate ...
Bruce K. Patterson, Ram Yogendra, Jose Guevara-Coto, Rodrigo A. Mora-Rodriguez, Eric Osgood, John Bream, Purvi Parikh, Mark Kreimer, Devon Jeffers, Cedric Rutland, Gary Kaplan, Michael Zgoda   +11 more
doaj   +1 more source